A new monacolin analogue from Xuezhikang capsule

Area of Science:

• Natural Product Chemistry
• Pharmacology
• Cardiovascular Medicine

Background:

• Xuezhikang, an ethanol extract of red yeast rice, is a traditional Chinese medicine.
• It exhibits 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibiting activity.
• Clinical trials show Xuezhikang lowers lipids and reduces cardiac events and mortality in Chinese coronary heart disease patients.

Purpose of the Study:

• To elucidate the chemical constituents of Xuezhikang.
• To provide a precise chemical explanation for its clinical effects.

Main Methods:

• Isolation and purification of chemical compounds from Xuezhikang.
• Structure elucidation using extensive 1D and 2D NMR and Mass Spectrometry (MS) analyses.

Main Results:

• Isolation of a new monacolin analogue, alpha, beta-dehydromonacolin L (1).
• Identification of two known compounds: monacolin L (2) and 3-(2, 6-dimethyl-1, 2, 4a, 5, 6, 7, 8, 8a-octahydronaphthalen-1-yl)propanoic acid (3).
• Chemical structures were confirmed through comprehensive spectroscopic analysis.

Conclusions:

• The chemical characterization of Xuezhikang provides a basis for understanding its pharmacological activity.
• The identified compounds, including the novel analogue, contribute to the lipid-lowering effects of Xuezhikang.
• Further research can explore the therapeutic potential of these constituents in cardiovascular health.